{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:31Z","timestamp":1790898931207,"version":"4.1.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CMMI 1851635"],"award-info":[{"award-number":["CMMI 1851635"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["ECCS 2021081"],"award-info":[{"award-number":["ECCS 2021081"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nanoparticle (NP)-based drug delivery systems offer promising solutions for neurodegenerative diseases such as Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s, which have no cure due to the brain\u2019s structural complexity and the restrictive nature of the blood-brain barrier (BBB). Conventional therapeutics, despite strong\n                    <jats:italic>in vitro<\/jats:italic>\n                    efficacy, often fail clinically due to poor brain penetration. Recent advances in NP engineering, including optimization of size (10\u2013100\u00a0nm), surface charge (-10 to -20\u00a0mV), and targeted ligand decoration, have improved BBB crossing and reduced premature clearance. In parallel, predictive in silico approaches, such as physiologically based pharmacokinetic (PBPK) modeling, computational fluid dynamics, and machine learning models, enable quantitative prediction of NP biodistribution, residence times, and region-specific uptake. By simulating key determinants, including blood flow dynamics, vasculature heterogeneity, permeability, and retention, these computational tools accelerate lead selection, reduce experimental burden, and inform design before\n                    <jats:italic>in vivo<\/jats:italic>\n                    testing. This review integrates recent progress in NP design with advanced computational modeling, highlighting how their convergence provides a rational framework for developing next-generation brain-targeted therapeutics. We further discuss regulatory and translational challenges, including safety, biocompatibility, and the need for humanized preclinical benchmarks. Together, these innovations offer a roadmap for advancing NP-based strategies toward clinical impact in neurodegenerative disease.\n                  <\/jats:p>","DOI":"10.1007\/s11095-026-04201-5","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:58Z","timestamp":1790889958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Design to Bedside: Brain-Targeted Engineered Nanoparticles and Predictive Modeling for Neurodegenerative Diseases Therapeutics"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-7243","authenticated-orcid":false,"given":"Nguyen","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzhaozi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-4638","authenticated-orcid":false,"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"4201_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/dta.301","volume":"3","author":"AW Jones","year":"2011","unstructured":"Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3:337\u201344.","journal-title":"Drug Test Anal"},{"key":"4201_CR2","doi-asserted-by":"crossref","unstructured":"Kaiser C. Pharmaceutical innovation. revolutionizing human health Edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine. Chemical Heritage Press, Philadelphia. 1999. xxiii+ 408 pp. 16\u00d7 24 cm. ISBN 0-941901-21-1. $44.95, ACS Publications, 2000.","DOI":"10.1021\/jm000120h"},{"key":"4201_CR3","doi-asserted-by":"publisher","first-page":"042004","DOI":"10.1088\/2516-1091\/abb008","volume":"2","author":"GM Xiong","year":"2020","unstructured":"Xiong GM, Venkatraman K, Venkatraman S. The magic bullet as cancer therapeutic\u2014has nanotechnology failed to find its mark? Prog Biomed Eng. 2020;2:042004.","journal-title":"Prog Biomed Eng"},{"key":"4201_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1228679","volume":"11","author":"L Hu","year":"2023","unstructured":"Hu L, Tao Y, Jiang Y, Qin F. Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. 2023;11:1228679.","journal-title":"Front Cell Dev Biol"},{"key":"4201_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22169082","volume":"22","author":"K Jagaran","year":"2021","unstructured":"Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: focus on Alzheimer\u2019s and Parkinson\u2019s diseases. Int J Mol Sci. 2021;22:9082.","journal-title":"Int J Mol Sci"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"35223","DOI":"10.1021\/acsomega.4c01774","volume":"9","author":"O Ozceylan","year":"2024","unstructured":"Ozceylan O, Sezgin-Bayindir Z. Current overview on the use of nanosized drug delivery systems in the treatment of neurodegenerative diseases. ACS Omega. 2024;9:35223\u201342.","journal-title":"ACS Omega"},{"key":"4201_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217.","journal-title":"Signal Transduct Target Ther"},{"key":"4201_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111654","volume":"22","author":"RGR Pinheiro","year":"2021","unstructured":"Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci. 2021;22:11654.","journal-title":"Int J Mol Sci"},{"key":"4201_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s11064-020-03031-0","volume":"45","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TTD, Le TT, Vo VG. Role of insulin resistance in the Alzheimer\u2019s disease progression. Neurochem Res. 2020;45:1481\u201391.","journal-title":"Neurochem Res"},{"key":"4201_CR10","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/anie.200802808","volume":"48","author":"R Jakob-Roetne","year":"2009","unstructured":"Jakob-Roetne R, Jacobsen H. Alzheimer\u2019s disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl. 2009;48:3030\u201359.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4201_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00002512-200825020-00008","volume":"25","author":"RS Doody","year":"2008","unstructured":"Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg\/day: results from a pilot study in patients with Alzheimer\u2019s disease. Drugs Aging. 2008;25:163\u201374.","journal-title":"Drugs Aging"},{"key":"4201_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"K-X Dou","year":"2018","unstructured":"Dou K-X, Tan M-S, Tan C-C, Cao X-P, Hou X-H, Guo Q-H, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10:1\u201310.","journal-title":"Alzheimers Res Ther"},{"key":"4201_CR13","unstructured":"Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;CD001747."},{"key":"4201_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-2011-101929","volume":"25","author":"JB Schulz","year":"2011","unstructured":"Schulz JB, Rainer M, Kl\u00fcnemann H-H, Kurz A, Wolf S, Sternberg K, et al. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer\u2019s disease: results of a 16-week open-label trial. J Alzheimers Dis. 2011;25:463\u201375.","journal-title":"J Alzheimers Dis"},{"key":"4201_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer WJ. The synaptic pathology of \u03b1-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 2010;120:131\u201343.","journal-title":"Acta Neuropathol"},{"key":"4201_CR16","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46:S30\u20133.","journal-title":"Parkinsonism Relat Disord"},{"key":"4201_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72:S1\u2013136.","journal-title":"Neurology"},{"key":"4201_CR18","doi-asserted-by":"crossref","unstructured":"G. Parkinson Study. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498\u20132508","DOI":"10.1056\/NEJMoa033447"},{"key":"4201_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000449184","volume":"23","author":"N Kaur","year":"2016","unstructured":"Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23:176\u201385.","journal-title":"Ann Neurosci"},{"key":"4201_CR20","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509\u201323.","journal-title":"Expert Rev Neurother"},{"key":"4201_CR21","doi-asserted-by":"crossref","unstructured":"Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB. Aducanumab therapy to treat Alzheimer\u2019s disease: a narrative review. Int J Alzheimer\u2019s Dis. 2022;2022.","DOI":"10.1155\/2022\/9343514"},{"key":"4201_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101547","author":"MDM Marsool","year":"2023","unstructured":"Marsool MDM, Prajjwal P, Reddy YB, Marsool ADM, Lam JR, Nandwana V. Newer modalities in the management of Alzheimer\u2019s dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Dis Mon. 2023. https:\/\/doi.org\/10.1016\/j.disamonth.2023.101547.","journal-title":"Dis Mon"},{"key":"4201_CR23","unstructured":"Singh R, Parmar M. Pramipexole. StatPearls [Internet]. StatPearls Publishing; 2023."},{"key":"4201_CR24","unstructured":"Rewane A, Nagalli S. Ropinirole. StatPearls [Internet]. StatPearls Publishing; 2022."},{"key":"4201_CR25","unstructured":"Moore JJ, Saadabadi A. Selegiline. In: 2023 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"4201_CR26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947\u201354.","journal-title":"Lancet"},{"key":"4201_CR27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","volume":"77","author":"Y-A Heo","year":"2017","unstructured":"Heo Y-A, Scott LJ. Deutetrabenazine: a review in chorea associated with Huntington\u2019s disease. Drugs. 2017;77:1857\u201364.","journal-title":"Drugs"},{"key":"4201_CR28","unstructured":"Rosenblatt A, Ranen NG, Nance MA, Paulsen JS. A physician's guide to the management of Huntington disease. Ligue Huntington francophone Belge; 1999."},{"key":"4201_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010949","volume":"5","author":"D Dell'Orco","year":"2010","unstructured":"Dell\u2019Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS ONE. 2010;5:e10949.","journal-title":"PLoS ONE"},{"key":"4201_CR30","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1039\/C4CC07644C","volume":"51","author":"J Lazarovits","year":"2015","unstructured":"Lazarovits J, Chen YY, Sykes EA, Chan WCW. Nanoparticle\u2013blood interactions: the implications on solid tumour targeting. Chem Commun. 2015;51:2756\u201367.","journal-title":"Chem Commun"},{"key":"4201_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.118.016816","volume":"71","author":"JLS Au","year":"2019","unstructured":"Au JLS, Abbiati RA, Wientjes MG, Lu Z. Target site delivery and residence of nanomedicines: application of quantitative systems pharmacology. Pharmacol Rev. 2019;71:157\u201369.","journal-title":"Pharmacol Rev"},{"key":"4201_CR32","doi-asserted-by":"crossref","unstructured":"Morshed N, Rennie C, Faria M, Collins-Praino L, Care A. Protein coronas derived from cerebrospinal fluid enhance the interactions between nanoparticles and brain cells. BioRxiv. 2024:2024\u201305.","DOI":"10.1101\/2024.05.31.596763"},{"key":"4201_CR33","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1039\/C8NR09891C","volume":"11","author":"H Moustaoui","year":"2019","unstructured":"Moustaoui H, Saber J, Djeddi I, Liu Q, Movia D, Prina-Mello A, et al. A protein corona study by scattering correlation spectroscopy: a comparative study between spherical and urchin-shaped gold nanoparticles. Nanoscale. 2019;11:3665\u201373.","journal-title":"Nanoscale"},{"key":"4201_CR34","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1021\/acs.nanolett.2c04501","volume":"23","author":"ZP Lin","year":"2023","unstructured":"Lin ZP, Ngo W, Mladjenovic SM, Wu JLY, Chan WCW. Nanoparticles bind to endothelial cells in injured blood vessels via a transient protein corona. Nano Lett. 2023;23:1003\u20139.","journal-title":"Nano Lett"},{"key":"4201_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1210\/en.2009-1082","volume":"151","author":"BS Zolnik","year":"2010","unstructured":"Zolnik BS, Gonz\u00e1lez-Fern\u00e1ndez \u00c1, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology. 2010;151:458\u201365.","journal-title":"Endocrinology"},{"issue":"2","key":"4201_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jconrel.2012.04.044","volume":"164","author":"S Krol","year":"2012","unstructured":"Krol S. Challenges in drug delivery to the brain: nature is against us. J Control Release. 2012;164(2):145\u201355.","journal-title":"J Control Release"},{"issue":"19","key":"4201_CR37","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/smll.201000763","volume":"6","author":"SJ Soenen","year":"2010","unstructured":"Soenen SJ, Himmelreich U, Nuytten N, Pisanic TR, Ferrari A, De Cuyper M. Intracellular nanoparticle coating stability determines nanoparticle diagnostics efficacy and cell functionality. Small. 2010;6(19):2136\u201345.","journal-title":"Small"},{"key":"4201_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11051-014-2376-4","author":"R Pamies","year":"2014","unstructured":"Pamies R, Cifre JGH, Esp\u00edn VF, Collado-Gonz\u00e1lez M, Ba\u00f1os FGD, de la Torre JG. Aggregation behaviour of gold nanoparticles in saline aqueous media. J Nanopart Res. 2014. https:\/\/doi.org\/10.1007\/s11051-014-2376-4.","journal-title":"J Nanopart Res"},{"key":"4201_CR39","first-page":"29","volume":"9","author":"K-M Kim","year":"2014","unstructured":"Kim K-M, Kim HM, Lee W-J, Lee C-W, Kim T-I, Lee J-K, et al. Surface treatment of silica nanoparticles for stable and charge-controlled colloidal silica. Int J Nanomed. 2014;9:29\u201340.","journal-title":"Int J Nanomed"},{"issue":"24","key":"4201_CR40","doi-asserted-by":"publisher","first-page":"1906274","DOI":"10.1002\/adma.201906274","volume":"32","author":"YY Chen","year":"2020","unstructured":"Chen YY, Syed AM, MacMillan P, Rocheleau JV, Chan WC. Flow rate affects nanoparticle uptake into endothelial cells. Adv Mater. 2020;32(24):1906274.","journal-title":"Adv Mater"},{"key":"4201_CR41","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cne.24040","volume":"524","author":"CS Von Bartheld","year":"2016","unstructured":"Von Bartheld CS, Bahney J, Herculano\u2010Houzel S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol. 2016;524:3865\u201395.","journal-title":"J Comp Neurol"},{"issue":"10","key":"4201_CR42","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","volume":"1788","author":"SD Li","year":"2009","unstructured":"Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2009;1788(10):2259\u201366.","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"key":"4201_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6564585","author":"A Alahmari","year":"2021","unstructured":"Alahmari A. Blood-brain barrier overview: structural and functional correlation. Neural Plast. 2021. https:\/\/doi.org\/10.1155\/2021\/6564585. ((2021)).","journal-title":"Neural Plast"},{"issue":"1","key":"4201_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1042\/BST20200611","volume":"49","author":"AM Clyne","year":"2021","unstructured":"Clyne AM. Endothelial response to glucose: dysfunction, metabolism, and transport. Biochem Soc Trans. 2021;49(1):313\u201325.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"4201_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood\u2013brain barrier. Neurobiol Dis. 2010;37(1):13\u201325.","journal-title":"Neurobiol Dis"},{"key":"4201_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2021.101957","volume":"114","author":"DN Jones","year":"2021","unstructured":"Jones DN, Raghanti MA. The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders. J Chem Neuroanat. 2021;114:101957.","journal-title":"J Chem Neuroanat"},{"issue":"3","key":"4201_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3727\/000000007783464731","volume":"16","author":"BS Desai","year":"2007","unstructured":"Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood\u2013brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007;16(3):285\u201399.","journal-title":"Cell Transplant"},{"issue":"2","key":"4201_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/08916930601183522","volume":"40","author":"J Correale","year":"2007","unstructured":"Correale J, Villa A. The blood\u2013brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity. 2007;40(2):148\u201360.","journal-title":"Autoimmunity"},{"issue":"1","key":"4201_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/156720208783565645","volume":"5","author":"C Kaur","year":"2008","unstructured":"Kaur C, Ling EA. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res. 2008;5(1):71\u201381.","journal-title":"Curr Neurovasc Res"},{"issue":"1","key":"4201_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/brain\/awh682","volume":"129","author":"S Remy","year":"2006","unstructured":"Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006;129(1):18\u201335.","journal-title":"Brain"},{"key":"4201_CR51","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00050.2017","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2018. https:\/\/doi.org\/10.1152\/physrev.00050.2017.","journal-title":"Physiol Rev"},{"key":"4201_CR52","doi-asserted-by":"crossref","unstructured":"Birgit Obermeier RD, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier \u2013 PubMed. Nat Med. 2013:19.","DOI":"10.1038\/nm.3407"},{"issue":"7816","key":"4201_CR53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","volume":"583","author":"AC Yang","year":"2020","unstructured":"Yang AC, Stevens MY, Chen MB, Lee DP, St\u00e4hli D, Gate D, et al. Physiological blood\u2013brain transport is impaired with age by a shift in transcytosis. Nature. 2020;583(7816):425\u201330.","journal-title":"Nature"},{"key":"4201_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-024-01529-1","volume":"16","author":"L Preis","year":"2024","unstructured":"Preis L, Villringer K, Brosseron F, D\u00fczel E, Jessen F, Petzold GC, et al. Assessing blood-brain barrier dysfunction and its association with Alzheimer\u2019s pathology, cognitive impairment and neuroinflammation. Alzheimers Res Ther. 2024;16:172.","journal-title":"Alzheimers Res Ther"},{"key":"4201_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.593026","volume":"11","author":"S Al-Bachari","year":"2020","unstructured":"Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM. Blood\u2013brain barrier leakage is increased in Parkinson\u2019s disease. Front Physiol. 2020;11:593026.","journal-title":"Front Physiol"},{"key":"4201_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2024.215926","volume":"514","author":"Z Han","year":"2024","unstructured":"Han Z, Yuan M, Nguyen N, Zhou H-C, Hubbard JE Jr, Wang Y. Brain-specific targeted delivery of therapeutic agents using metal\u2013organic framework-based nanomedicine. Coord Chem Rev. 2024;514:215926.","journal-title":"Coord Chem Rev"},{"key":"4201_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/nnm.11.25","volume":"6","author":"Y-C Kuo","year":"2011","unstructured":"Kuo Y-C, Lin P-I, Wang C-C. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly (lactide-co-glycolide) nanoparticles. Nanomedicine (Lond). 2011;6:1011\u201326.","journal-title":"Nanomedicine (Lond)"},{"key":"4201_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2008.10.016","volume":"134","author":"K Hu","year":"2009","unstructured":"Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG\u2013PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55\u201361.","journal-title":"J Control Release"},{"key":"4201_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-12-386986-9.00003-X","volume":"102","author":"HS Sharma","year":"2012","unstructured":"Sharma HS, Castellani RJ, Smith MA, Sharma A. The blood-brain barrier in Alzheimer\u2019s disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol. 2012;102:47\u201390.","journal-title":"Int Rev Neurobiol"},{"key":"4201_CR60","doi-asserted-by":"crossref","unstructured":"Salehi B, Calina D, Docea AO, Koirala N, Aryal S, Lombardo D, Pasqua L, Taheri Y, Marina Salgado Castillo C, Martorell M. Curcumin\u2019s nanomedicine formulations for therapeutic application in neurological diseases. J Clin Med. 2020;9:430.","DOI":"10.3390\/jcm9020430"},{"key":"4201_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/ijms22010196","volume":"22","author":"U Shabbir","year":"2020","unstructured":"Shabbir U, Rubab M, Tyagi A, Oh D-H. Curcumin and its derivatives as theranostic agents in Alzheimer\u2019s disease: the implication of nanotechnology. Int J Mol Sci. 2020;22:196.","journal-title":"Int J Mol Sci"},{"key":"4201_CR62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/ph17050612","volume":"17","author":"E Asimakidou","year":"2024","unstructured":"Asimakidou E, Tan JKS, Zeng J, Lo CH. Blood-brain barrier-targeting nanoparticles: biomaterial properties and biomedical applications in translational neuroscience. Pharmaceuticals. 2024;17:612.","journal-title":"Pharmaceuticals"},{"key":"4201_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/pharmaceutics15010200","volume":"15","author":"AM Ross","year":"2023","unstructured":"Ross AM, Cahalane RM, Walsh DR, Grabrucker AM, Marcar L, Mulvihill JJE. Identification of nanoparticle properties for optimal drug delivery across a physiological cell barrier. Pharmaceutics. 2023;15:200.","journal-title":"Pharmaceutics"},{"key":"4201_CR64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2020.04.054","volume":"324","author":"MC Rich","year":"2020","unstructured":"Rich MC, Sherwood J, Bartley AF, Whitsitt QA, Lee M, Willoughby WR, et al. Focused ultrasound blood brain barrier opening mediated delivery of MRI-visible albumin nanoclusters to the rat brain for localized drug delivery with temporal control. J Control Release. 2020;324:172\u201380.","journal-title":"J Control Release"},{"key":"4201_CR65","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.7150\/thno.21630","volume":"7","author":"D McMahon","year":"2017","unstructured":"McMahon D, Hynynen K. Acute inflammatory response following increased blood-brain barrier permeability induced by focused ultrasound is dependent on microbubble dose. Theranostics. 2017;7:3989.","journal-title":"Theranostics"},{"issue":"1","key":"4201_CR66","first-page":"1087250","volume":"2016","author":"X Yu","year":"2016","unstructured":"Yu X, Trase I, Ren M, Duval K, Guo X, Chen Z. Design of nanoparticle-based carriers for targeted drug delivery. J Nanomater. 2016;2016(1):1087250.","journal-title":"J Nanomater"},{"key":"4201_CR67","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2217\/nnm.15.52","volume":"10","author":"R Guduru","year":"2015","unstructured":"Guduru R, Liang P, Hong J, Rodzinski A, Hadjikhani A, Horstmyer J, et al. Magnetoelectric \u2018spin\u2019on stimulating the brain. Nanomedicine (Lond). 2015;10:2051\u201361.","journal-title":"Nanomedicine (Lond)"},{"key":"4201_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/srep25309","volume":"6","author":"A Kaushik","year":"2016","unstructured":"Kaushik A, Jayant RD, Nikkhah-Moshaie R, Bhardwaj V, Roy U, Huang Z, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep. 2016;6:25309.","journal-title":"Sci Rep"},{"key":"4201_CR69","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1021\/acsabm.9b00592","volume":"2","author":"A Kaushik","year":"2019","unstructured":"Kaushik A, Rodriguez J, Rothen D, Bhardwaj V, Jayant RD, Pattany P, et al. MRI-guided, noninvasive delivery of magneto-electric drug nanocarriers to the brain in a nonhuman primate. ACS Appl Bio Mater. 2019;2:4826\u201336.","journal-title":"ACS Appl Bio Mater"},{"key":"4201_CR70","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jconrel.2022.03.007","volume":"345","author":"J Chen","year":"2022","unstructured":"Chen J, Yuan M, Madison CA, Eitan S, Wang Y. Blood-brain barrier crossing using magnetic stimulated nanoparticles. J Control Release. 2022;345:557\u201371.","journal-title":"J Control Release"},{"issue":"3","key":"4201_CR71","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s42114-022-00444-z","volume":"5","author":"M Yuan","year":"2022","unstructured":"Yuan M, Feng X, Yan TH, Chen J, Ma X, Cunha P, et al. Superparamagnetic iron oxide-enclosed hollow gold nanostructure with tunable surface plasmon resonances to promote near-infrared photothermal conversion. Adv Compos Hybrid Mater. 2022;5(3):2387\u201398.","journal-title":"Adv Compos Hybrid Mater"},{"key":"4201_CR72","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/17425247.2014.924501","volume":"11","author":"S Laurent","year":"2014","unstructured":"Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv. 2014;11:1449\u201370.","journal-title":"Expert Opin Drug Deliv"},{"key":"4201_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070630","volume":"12","author":"SH Pham","year":"2020","unstructured":"Pham SH, Choi Y, Choi J. Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery. Pharmaceutics. 2020;12:630.","journal-title":"Pharmaceutics"},{"key":"4201_CR74","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1021\/ja303280r","volume":"134","author":"D-S Guo","year":"2012","unstructured":"Guo D-S, Wang K, Wang Y-X, Liu Y. Cholinesterase-responsive supramolecular vesicle. J Am Chem Soc. 2012;134:10244\u201350.","journal-title":"J Am Chem Soc"},{"key":"4201_CR75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.actbio.2021.01.018","volume":"123","author":"W Liu","year":"2021","unstructured":"Liu W, Dong X, Liu Y, Sun Y. Photoresponsive materials for intensified modulation of Alzheimer\u2019s amyloid-\u03b2 protein aggregation: a review. Acta Biomater. 2021;123:93\u2013109.","journal-title":"Acta Biomater"},{"key":"4201_CR76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/antiox12030703","volume":"12","author":"Y Min","year":"2023","unstructured":"Min Y, Suminda GGD, Heo Y, Kim M, Ghosh M, Son Y-O. Metal-based nanoparticles and their relevant consequences on cytotoxicity cascade and induced oxidative stress. Antioxidants (Basel). 2023;12:703.","journal-title":"Antioxidants (Basel)"},{"key":"4201_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtcomm.2023.106244","volume":"35","author":"N Rabiee","year":"2023","unstructured":"Rabiee N. Sustainable metal-organic frameworks (MOFs) for drug delivery systems. Mater Today Commun. 2023;35:106244.","journal-title":"Mater Today Commun"},{"key":"4201_CR78","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377\u201397.","journal-title":"Polymers (Basel)"},{"key":"4201_CR79","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/pharmaceutics15041313","volume":"15","author":"N Desai","year":"2023","unstructured":"Desai N, Rana D, Salave S, Gupta R, Patel P, Karunakaran B, et al. Chitosan: a potential biopolymer in drug delivery and biomedical applications. Pharmaceutics. 2023;15:1313.","journal-title":"Pharmaceutics"},{"key":"4201_CR80","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","volume":"11","author":"CP Costa","year":"2021","unstructured":"Costa CP, Moreira JN, Lobo JMS, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B. 2021;11:925\u201340.","journal-title":"Acta Pharm Sin B"},{"key":"4201_CR81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","volume":"268","author":"AL Klibanov","year":"1990","unstructured":"Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235\u20137.","journal-title":"FEBS Lett"},{"key":"4201_CR82","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s442877","author":"X Han","year":"2024","unstructured":"Han X, Gong C, Yang Q, Zheng K, Wang Z, Zhang W. Biomimetic nano-drug delivery system: an emerging platform for promoting tumor treatment. Int J Nanomed. 2024. https:\/\/doi.org\/10.2147\/ijn.s442877.","journal-title":"Int J Nanomed"},{"key":"4201_CR83","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.apsb.2019.01.011","volume":"9","author":"Q Xia","year":"2019","unstructured":"Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B. 2019;9:675\u201389.","journal-title":"Acta Pharm Sin B"},{"key":"4201_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.impact.2020.100261","volume":"20","author":"S Fu","year":"2020","unstructured":"Fu S, Wang Y, Xia X, Zheng JC. Exosome engineering: current progress in cargo loading and targeted delivery. NanoImpact. 2020;20:100261.","journal-title":"NanoImpact"},{"key":"4201_CR85","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jconrel.2022.08.002","volume":"349","author":"C Li","year":"2022","unstructured":"Li C, Qin S, Wen Y, Zhao W, Huang Y, Liu J. Overcoming the blood-brain barrier: exosomes as theranostic nanocarriers for precision neuroimaging. J Control Release. 2022;349:902\u201316.","journal-title":"J Control Release"},{"key":"4201_CR86","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1016\/j.biomaterials.2010.05.009","volume":"31","author":"J Lipka","year":"2010","unstructured":"Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010;31:6574\u201381.","journal-title":"Biomaterials"},{"key":"4201_CR87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0165-0173(01)00098-4","volume":"36","author":"AD Zurn","year":"2001","unstructured":"Zurn AD, Widmer HR, Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson\u2019s disease. Brain Res Rev. 2001;36:222\u20139.","journal-title":"Brain Res Rev"},{"key":"4201_CR88","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neubiorev.2009.11.009","volume":"35","author":"UE Ghitza","year":"2010","unstructured":"Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev. 2010;35:157\u201371.","journal-title":"Neurosci Biobehav Rev"},{"key":"4201_CR89","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1073\/pnas.1304504110","volume":"110","author":"J Zhou","year":"2013","unstructured":"Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng M-Q, Duong N, et al. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 2013;110:11751\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4201_CR90","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.nano.2017.06.010","volume":"13","author":"D Yurek","year":"2017","unstructured":"Yurek D, Hasselrot U, Sesenoglu-Laird O, Padegimas L, Cooper M. Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration. Nanomedicine (Lond). 2017;13:2209\u201317.","journal-title":"Nanomedicine (Lond)"},{"issue":"2","key":"4201_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20240036","volume":"5","author":"X Wang","year":"2025","unstructured":"Wang X, Yin Y, Zhou H, Chi B, Guan L, Li P, et al. Drug delivery pathways to the central nervous system via the brain glymphatic system circumventing the blood-brain barrier. Exploration. 2025;5(2):20240036.","journal-title":"Exploration"},{"key":"4201_CR92","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","volume":"165","author":"MJ Fowler","year":"2020","unstructured":"Fowler MJ, Cotter JD, Knight BE, Sevick-Muraca EM, Sandberg DI, Sirianni RW. Intrathecal drug delivery in the era of nanomedicine. Adv Drug Deliv Rev. 2020;165:77\u201395.","journal-title":"Adv Drug Deliv Rev"},{"key":"4201_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17425247.2020.1698544","volume":"17","author":"G Tosi","year":"2020","unstructured":"Tosi G, Duskey JT, Kreuter J. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 2020;17:23\u201332.","journal-title":"Expert Opin Drug Deliv"},{"key":"4201_CR94","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0196-9781(97)00474-9","volume":"19","author":"U Schroeder","year":"1998","unstructured":"Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood\u2013brain barrier. Peptides. 1998;19:777\u201380.","journal-title":"Peptides"},{"issue":"9","key":"4201_CR95","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","volume":"12","author":"EM Pridgen","year":"2015","unstructured":"Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert opinion on drug delivery. 2015;12(9):1459\u201373.","journal-title":"Expert opinion on drug delivery"},{"key":"4201_CR96","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","volume":"150","author":"G Mittal","year":"2011","unstructured":"Mittal G, Carswell H, Brett R, Currie S, Kumar MNVR. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology. J Control Release. 2011;150:220\u20138.","journal-title":"J Control Release"},{"key":"4201_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010018","volume":"13","author":"R New","year":"2020","unstructured":"New R. Oral delivery of biologics via the intestine. Pharmaceutics. 2020;13:18.","journal-title":"Pharmaceutics"},{"key":"4201_CR98","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s11095-010-0291-7","volume":"28","author":"I Van Rooy","year":"2011","unstructured":"Van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharm Res. 2011;28:456\u201371.","journal-title":"Pharm Res"},{"key":"4201_CR99","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994;91:5705\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4201_CR100","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/jpet.102.036129","volume":"302","author":"WA Banks","year":"2002","unstructured":"Banks WA, Goulet M, Rusche JR, Niehoff ML, Boismenu R. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J Pharmacol Exp Ther. 2002;302:1062\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"4201_CR101","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11095-022-03185-2","volume":"39","author":"JM Wasielewska","year":"2022","unstructured":"Wasielewska JM, White AR. Focused ultrasound-mediated drug delivery in humans\u2013a path towards translation in neurodegenerative diseases. Pharm Res. 2022;39:427\u201339.","journal-title":"Pharm Res"},{"key":"4201_CR102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2020","unstructured":"Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res. 2020;37:12.","journal-title":"Pharm Res"},{"key":"4201_CR103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1211\/0022357055380","volume":"57","author":"T Shimada","year":"2005","unstructured":"Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol. 2005;57:177\u201381.","journal-title":"J Pharm Pharmacol"},{"key":"4201_CR104","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/dmd.118.080697","volume":"46","author":"MR Durk","year":"2018","unstructured":"Durk MR, Deshmukh G, Valle N, Ding X, Liederer BM, Liu X. Use of subcutaneous and intraperitoneal administration methods to facilitate cassette dosing in microdialysis studies in rats. Drug Metab Dispos. 2018;46:964\u20139.","journal-title":"Drug Metab Dispos"},{"key":"4201_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.994877","volume":"14","author":"P Bechinger","year":"2023","unstructured":"Bechinger P, Serrano Sponton L, Gr\u00fctzner V, Musyanovych A, Jussen D, Krenzlin H, et al. In-vivo time course of organ uptake and blood-brain-barrier permeation of poly (L-lactide) and poly (perfluorodecyl acrylate) nanoparticles with different surface properties in unharmed and brain-traumatized rats. Front Neurol. 2023;14:994877.","journal-title":"Front Neurol"},{"key":"4201_CR106","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1021\/mp400004a","volume":"10","author":"RK Sumbria","year":"2013","unstructured":"Sumbria RK, Zhou Q-H, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol Pharm. 2013;10:1425\u201331.","journal-title":"Mol Pharm"},{"key":"4201_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42114-025-01227-y","volume":"8","author":"M Yuan","year":"2025","unstructured":"Yuan M, Han Z, Somayaji Y, Nguyen N, Hu H, Madhu LN, et al. Intranasal delivery of metformin using metal\u2013organic framework (MOF)-74-Mg nanocarriers. Adv Compos Hybrid Mater. 2025;8:1\u201315.","journal-title":"Adv Compos Hybrid Mater"},{"key":"4201_CR108","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/10717549709051892","volume":"4","author":"P Sigurdsson","year":"1997","unstructured":"Sigurdsson P, Thorvaldsson T, Gizurarson S, Gunnarsson E. Olfactory absorption of insulin to the brain. Drug Deliv. 1997;4:195\u2013200.","journal-title":"Drug Deliv"},{"key":"4201_CR109","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","volume":"15","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Furubayashi T, Arai M, Inoue D, Kimura S, Kiriyama A, et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application. Mol Pharm. 2018;15:1105\u201311.","journal-title":"Mol Pharm"},{"key":"4201_CR110","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6NR07581A","volume":"9","author":"E Ahmad","year":"2017","unstructured":"Ahmad E, Feng Y, Qi J, Fan W, Ma Y, He H, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale. 2017;9:1174\u201383.","journal-title":"Nanoscale"},{"key":"4201_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2022.101631","volume":"29","author":"ML Formica","year":"2022","unstructured":"Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022;29:101631.","journal-title":"Appl Mater Today"},{"key":"4201_CR112","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s102500","author":"AM Fatouh","year":"2017","unstructured":"Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther. 2017. https:\/\/doi.org\/10.2147\/dddt.s102500.","journal-title":"Drug Des Devel Ther"},{"key":"4201_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119148","volume":"579","author":"SK Bhattamisra","year":"2020","unstructured":"Bhattamisra SK, Shak AT, Xi LW, Safian NH, Choudhury H, Lim WM, et al. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease. Int J Pharm. 2020;579:119148.","journal-title":"Int J Pharm"},{"key":"4201_CR114","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","volume":"34","author":"Z Liu","year":"2013","unstructured":"Liu Z, Jiang M, Kang T, Miao D, Gu G, Song Q, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials. 2013;34:3870\u201381.","journal-title":"Biomaterials"},{"key":"4201_CR115","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/pharmaceutics14061136","volume":"14","author":"AI Petkova","year":"2022","unstructured":"Petkova AI, Kubajewska I, Vaideanu A, Sch\u00e4tzlein AG, Uchegbu IF. Gene targeting to the cerebral cortex following intranasal administration of polyplexes. Pharmaceutics. 2022;14:1136.","journal-title":"Pharmaceutics"},{"key":"4201_CR116","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/1389200217666160406120509","volume":"17","author":"P Oliveira","year":"2016","unstructured":"Oliveira P, Fortuna A, Alves G, Falcao A. Drug-metabolizing enzymes and efflux transporters in nasal epithelium: influence on the bioavailability of intranasally administered drugs. Curr Drug Metab. 2016;17:628\u201347.","journal-title":"Curr Drug Metab"},{"key":"4201_CR117","doi-asserted-by":"crossref","unstructured":"Fan Y, Chen M, Zhang J, Maincent P, Xia X, Wu W. Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases. Crit Rev Ther Drug Carr Syst. 2018;35(5):433\u201367.","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697"},{"key":"4201_CR118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"E Marttin","year":"1998","unstructured":"Marttin E, Schipper NGM, Verhoef JC, Merkus FWHM. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29:13\u201338.","journal-title":"Adv Drug Deliv Rev"},{"key":"4201_CR119","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","volume":"327","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Gupta U, et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J Control Release. 2020;327:235\u201365.","journal-title":"J Control Release"},{"key":"4201_CR120","first-page":"439","volume":"10","author":"JT Trevino","year":"2020","unstructured":"Trevino JT, Quispe RC, Khan F, Novak V. Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials. 2020;10:439.","journal-title":"J Clin Trials"},{"key":"4201_CR121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/17512433.2018.1477586","volume":"11","author":"A Rodallec","year":"2018","unstructured":"Rodallec A, Fanciullino R, Lacarelle B, Ciccolini J. Seek and destroy: improving PK\/PD profiles of anticancer agents with nanoparticles. Expert Rev Clin Pharmacol. 2018;11:599\u2013610.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4201_CR122","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejps.2016.07.003","volume":"92","author":"A Lindqvist","year":"2016","unstructured":"Lindqvist A, Frid\u00e9n M, Hammarlund-Udenaes M. Pharmacokinetic considerations of nanodelivery to the brain: using modeling and simulations to predict the outcome of liposomal formulations. Eur J Pharm Sci. 2016;92:173\u201382.","journal-title":"Eur J Pharm Sci"},{"key":"4201_CR123","doi-asserted-by":"publisher","first-page":"8856","DOI":"10.1158\/1078-0432.CCR-05-1365","volume":"11","author":"RD Arnold","year":"2005","unstructured":"Arnold RD, Mager DE, Slack JE, Straubinger RM. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res. 2005;11:8856\u201365.","journal-title":"Clin Cancer Res"},{"key":"4201_CR124","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/ph19030456","volume":"19","author":"I Eydelman","year":"2026","unstructured":"Eydelman I, Ben-Shabat S, Sintov AC. Pharmacokinetic modeling of the \u201cnose-to-brain\u201d pathway as demonstrated by intranasal administration of cannabidiol-loaded nanoparticles. Pharmaceuticals (Basel). 2026;19:456.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4201_CR125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.xphs.2018.10.037","volume":"108","author":"D Yuan","year":"2019","unstructured":"Yuan D, He H, Wu Y, Fan J, Cao Y. Physiologically based pharmacokinetic modeling of nanoparticles. J Pharm Sci. 2019;108:58\u201372.","journal-title":"J Pharm Sci"},{"key":"4201_CR126","first-page":"162","volume":"10","author":"Z Lin","year":"2016","unstructured":"Lin Z, Monteiro-Riviere NA, Riviere JE. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice. Nanotoxicology. 2016;10:162\u201372.","journal-title":"Nanotoxicology"},{"key":"4201_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2217\/nnm.15.177","volume":"11","author":"Z Lin","year":"2016","unstructured":"Lin Z, Monteiro-Riviere NA, Kannan R, Riviere JE. A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. Nanomedicine. 2016;11:107\u201319.","journal-title":"Nanomedicine"},{"key":"4201_CR128","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/pharmaceutics11040179","volume":"11","author":"M Aborig","year":"2019","unstructured":"Aborig M, Malik PRV, Nambiar S, Chelle P, Darko J, Mutsaers A, et al. Biodistribution and physiologically-based pharmacokinetic modeling of gold nanoparticles in mice with interspecies extrapolation. Pharmaceutics. 2019;11:179.","journal-title":"Pharmaceutics"},{"key":"4201_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114765","volume":"384","author":"L Deng","year":"2019","unstructured":"Deng L, Liu H, Ma Y, Miao Y, Fu X, Deng Q. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles. Toxicol Appl Pharmacol. 2019;384:114765.","journal-title":"Toxicol Appl Pharmacol"},{"key":"4201_CR130","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/psp4.12762","volume":"11","author":"AD Le","year":"2022","unstructured":"Le AD, Wearing HJ, Li D. Streamlining physiologically\u2010based pharmacokinetic model design for intravenous delivery of nanoparticle drugs. CPT Pharmacomet Syst Pharmacol. 2022;11:409\u201324.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"4201_CR131","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1021\/es800254a","volume":"42","author":"P Lin","year":"2008","unstructured":"Lin P, Chen J-W, Chang LW, Wu J-P, Redding L, Chang H, et al. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. Environ Sci Technol. 2008;42:6264\u201370.","journal-title":"Environ Sci Technol"},{"key":"4201_CR132","doi-asserted-by":"crossref","unstructured":"Li M, Panagi Z, Avgoustakis K, Reineke J. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomed. 2012:1345\u201356.","DOI":"10.2147\/IJN.S23758"},{"key":"4201_CR133","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10928-011-9200-x","volume":"38","author":"MD Thompson","year":"2011","unstructured":"Thompson MD, Beard DA. Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport. J Pharmacokinet Pharmacodyn. 2011;38:405\u201321.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4201_CR134","doi-asserted-by":"crossref","unstructured":"Bachler G, von Goetz N, Hungerb\u00fchler K. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomed. 2013:3365\u201382.","DOI":"10.2147\/IJN.S46624"},{"key":"4201_CR135","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/pharmaceutics16020226","volume":"16","author":"P Mehta","year":"2024","unstructured":"Mehta P, Soliman A, Rodriguez-Vera L, Schmidt S, Muniz P, Rodriguez M, et al. Interspecies brain pbpk modeling platform to predict passive transport through the blood\u2013brain barrier and assess target site disposition. Pharmaceutics. 2024;16:226.","journal-title":"Pharmaceutics"},{"key":"4201_CR136","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40262-016-0367-6","volume":"55","author":"S Alqahtani","year":"2016","unstructured":"Alqahtani S, Kaddoumi A. Development of a physiologically based pharmacokinetic\/pharmacodynamic model to predict the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics represented by receptor\/transporter occupancy of central nervous system drugs. Clin Pharmacokinet. 2016;55:957\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"4201_CR137","unstructured":"Muliaditan M, van Steeg TJ, Avery LB, Sun W, Hammond TR, Hijdra D, Choi S-L, Pillai N, Leksa NC, Mavroudis PD. Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies. Taylor & Francis, pp. 2515414."},{"key":"4201_CR138","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/cpt.42","volume":"97","author":"A Parekh","year":"2015","unstructured":"Parekh A, Buckman-Garner S, McCune S, Oneill R, Geanacopoulos M, Amur S, et al. Catalyzing the critical path initiative: FDA\u2019s progress in drug development activities. Clin Pharmacol Ther. 2015;97:221\u201333.","journal-title":"Clin Pharmacol Ther"},{"key":"4201_CR139","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","volume":"58","author":"SA Peters","year":"2019","unstructured":"Peters SA, Dolgos H. Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them. Clin Pharmacokinet. 2019;58:1355\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"4201_CR140","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s42114-024-00884-9","volume":"7","author":"H Hu","year":"2024","unstructured":"Hu H, Yuan M, Chen J, Fan T, Nguyen N, Madison CA, et al. Pharmacokinetic modeling of solid and hollow gold-coated superparamagnetic iron oxide nanoparticles for brain-targeted therapeutics: prediction and experiment. Adv Compos Hybrid Mater. 2024;7:76.","journal-title":"Adv Compos Hybrid Mater"},{"key":"4201_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s42114-024-01013-2","author":"N Nguyen","year":"2024","unstructured":"Nguyen N, Yuan M, Hu H, Xiao Z, Fan T, Yan T-H, et al. Computational fluid-particle dynamic model guiding bioengineered magnetic nanomedicine for personalized brain-targeted drug delivery. Adv Compos Hybrid Mater. 2024. https:\/\/doi.org\/10.1007\/s42114-024-01013-2.","journal-title":"Adv Compos Hybrid Mater"},{"key":"4201_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/srep10649","volume":"5","author":"G Fullstone","year":"2015","unstructured":"Fullstone G, Wood J, Holcombe M, Battaglia G. Modelling the transport of nanoparticles under blood flow using an agent-based approach. Sci Rep. 2015;5:10649.","journal-title":"Sci Rep"},{"key":"4201_CR143","doi-asserted-by":"crossref","unstructured":"Perdikaris P, Grinberg L, Karniadakis GE. Multiscale modeling and simulation of brain blood flow. Phys Fluids. 2016:28.","DOI":"10.1063\/1.4941315"},{"key":"4201_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/fluids4040196","volume":"4","author":"LA Ray","year":"2019","unstructured":"Ray LA, Heys JJ. Fluid flow and mass transport in brain tissue. Fluids. 2019;4:196.","journal-title":"Fluids"},{"key":"4201_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012401","volume":"23","author":"EB Postnikov","year":"2022","unstructured":"Postnikov EB, Lavrova AI, Postnov DE. Transport in the brain extracellular space: diffusion, but which kind? Int J Mol Sci. 2022;23:12401.","journal-title":"Int J Mol Sci"},{"key":"4201_CR146","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1109\/TNB.2017.2737038","volume":"16","author":"A Bhandari","year":"2017","unstructured":"Bhandari A, Bansal A, Singh A, Sinha N. Transport of liposome encapsulated drugs in voxelized computational model of human brain tumors. IEEE Trans Nanobiosci. 2017;16:634\u201344.","journal-title":"IEEE Trans Nanobiosci"},{"key":"4201_CR147","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.jbiomech.2008.04.025","volume":"41","author":"AA Linninger","year":"2008","unstructured":"Linninger AA, Somayaji MR, Erickson T, Guo X, Penn RD. Computational methods for predicting drug transport in anisotropic and heterogeneous brain tissue. J Biomech. 2008;41:2176\u201387.","journal-title":"J Biomech"},{"key":"4201_CR148","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00304-4","volume":"19","author":"M Khani","year":"2022","unstructured":"Khani M, Burla GKR, Sass LR, Arters ON, Xing T, Wu H, et al. Human in silico trials for parametric computational fluid dynamics investigation of cerebrospinal fluid drug delivery: impact of injection location, injection protocol, and physiology. Fluids Barriers CNS. 2022;19:8.","journal-title":"Fluids Barriers CNS"},{"key":"4201_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082198","volume":"11","author":"R Boyuklieva","year":"2023","unstructured":"Boyuklieva R, Zagorchev P, Pilicheva B. Computational, in vitro, and in vivo models for nose-to-brain drug delivery studies. Biomedicines. 2023;11:2198.","journal-title":"Biomedicines"},{"key":"4201_CR150","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1166\/rnn.2012.1014","volume":"1","author":"Y Liu","year":"2012","unstructured":"Liu Y, Shah S, Tan J. Computational modeling of nanoparticle targeted drug delivery. Rev Nanosci Nanotechnol. 2012;1:66\u201383.","journal-title":"Rev Nanosci Nanotechnol"},{"key":"4201_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15100447","volume":"15","author":"P Vishnumurthy","year":"2025","unstructured":"Vishnumurthy P, Radulesco T, Bouchet G, Regard A, Michel J. Computational fluid dynamics approach for direct nose-to-brain drug delivery: a systematic review and meta-analysis. J Pers Med. 2025;15:447.","journal-title":"J Pers Med"},{"key":"4201_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2020.104103","volume":"128","author":"S Vachhani","year":"2021","unstructured":"Vachhani S, Kleinstreuer C. Comparison of micron-and nano-particle transport in the human nasal cavity with a focus on the olfactory region. Comput Biol Med. 2021;128:104103.","journal-title":"Comput Biol Med"},{"key":"4201_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.103048","volume":"68","author":"N Mahesh","year":"2022","unstructured":"Mahesh N, Singh N, Talukdar P. A mathematical model for understanding nanoparticle biodistribution after intratumoral injection in cancer tumors. J Drug Deliv Sci Technol. 2022;68:103048.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4201_CR154","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2217\/nnm.12.124","volume":"8","author":"SS Hossain","year":"2013","unstructured":"Hossain SS, Zhang Y, Liang X, Hussain F, Ferrari M, Hughes TJR, et al. In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine. 2013;8:343\u201357.","journal-title":"Nanomedicine"},{"key":"4201_CR155","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijpharm.2018.12.088","volume":"559","author":"A Shamloo","year":"2019","unstructured":"Shamloo A, Amani A, Forouzandehmehr M, Ghoytasi I. In silico study of patient-specific magnetic drug targeting for a coronary LAD atherosclerotic plaque. Int J Pharm. 2019;559:113\u201329.","journal-title":"Int J Pharm"},{"key":"4201_CR156","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1177\/0271678X17697340","volume":"37","author":"R Villase\u00f1or","year":"2017","unstructured":"Villase\u00f1or R, Kuennecke B, Ozmen L, Ammann M, Kugler C, Gr\u00fcninger F, et al. Region-specific permeability of the blood\u2013brain barrier upon pericyte loss. J Cereb Blood Flow Metab. 2017;37:3683\u201394.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4201_CR157","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G, Cryan JF, O\u2019Driscoll CM. The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27:2659\u201373.","journal-title":"Mol Psychiatry"},{"key":"4201_CR158","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350.","journal-title":"Nat Rev Neurol"},{"key":"4201_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108430","author":"FE Tarki","year":"2025","unstructured":"Tarki FE, Sharbatdar M, Zarrabi M, Vafaee F, Khanbabaei G. Computational insights into intranasal drug delivery: enhancing outcomes in pediatric cystic fibrosis. Respir Med. 2025. https:\/\/doi.org\/10.1016\/j.rmed.2025.108430.","journal-title":"Respir Med"},{"key":"4201_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.858126","volume":"16","author":"R Kumar","year":"2022","unstructured":"Kumar R, Sharma A, Alexiou A, Bilgrami AL, Kamal MA, Ashraf GM. DeePred-BBB: a blood brain barrier permeability prediction model with improved accuracy. Front Neurosci. 2022;16:858126.","journal-title":"Front Neurosci"},{"key":"4201_CR161","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/app15031166","volume":"15","author":"VV Kleandrova","year":"2025","unstructured":"Kleandrova VV, Cordeiro MNDS, Speck-Planche A. Perturbation-theory machine learning for multi-objective antibacterial discovery: current status and future perspectives. Appl Sci. 2025;15:1166.","journal-title":"Appl Sci"},{"key":"4201_CR162","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/ph16010081","volume":"16","author":"A Farnoud","year":"2023","unstructured":"Farnoud A, Tofighian H, Baumann I, Ahookhosh K, Pourmehran O, Cui X, et al. Numerical and machine learning analysis of the parameters affecting the regionally delivered nasal dose of nano-and micro-sized aerosolized drugs. Pharmaceuticals. 2023;16:81.","journal-title":"Pharmaceuticals"},{"key":"4201_CR163","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.xphs.2024.02.022","volume":"113","author":"S Zanganeh","year":"2024","unstructured":"Zanganeh S, Firoozpour L, Salavatipour MS, Sardari S, Cohan RA, Mohajel N. Critical aggregation concentration can be a predictor of doxorubicin delivery performance of self-assembling amphiphilic peptides with different hydrophobic tails. J Pharm Sci. 2024;113:2188\u201397.","journal-title":"J Pharm Sci"},{"key":"4201_CR164","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s344208","author":"Z Lin","year":"2022","unstructured":"Lin Z, Chou W-C, Cheng Y-H, He C, Monteiro-Riviere NA, Riviere JE. Predicting nanoparticle delivery to tumors using machine learning and artificial intelligence approaches. Int J Nanomed. 2022. https:\/\/doi.org\/10.2147\/ijn.s344208.","journal-title":"Int J Nanomed"},{"key":"4201_CR165","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1021\/acsami.0c18470","volume":"13","author":"AV Singh","year":"2020","unstructured":"Singh AV, Maharjan R-S, Kanase A, Siewert K, Rosenkranz D, Singh R, et al. Machine-learning-based approach to decode the influence of nanomaterial properties on their interaction with cells. ACS Appl Mater Interfaces. 2020;13:1943\u201355.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4201_CR166","volume-title":"Medical imaging with deep learning","author":"MM Billah","year":"2024","unstructured":"Billah MM, Manandhar P, Krishan S, G\u00e1mez AC, Rexha H, Lafond S, et al. Explainability in deep learning segmentation models for breast cancer by analogy with texture analysis. In: Medical imaging with deep learning; 2024."},{"key":"4201_CR167","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, Zhao J, Wang H, Li B, Li K, Shi X, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. 2020;11:4790.","journal-title":"Nat Commun"},{"key":"4201_CR168","doi-asserted-by":"publisher","first-page":"19077","DOI":"10.1038\/s41598-024-69324-4","volume":"14","author":"Y Yeni","year":"2024","unstructured":"Yeni Y, Genc S, Ertugrul MS, Nadaroglu H, Gezer A, Mendil AS, et al. Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-\u0131nduced Parkinson\u2019s disease. Sci Rep. 2024;14:19077.","journal-title":"Sci Rep"},{"key":"4201_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18071166","volume":"18","author":"H Alatawi","year":"2026","unstructured":"Alatawi H, Nair HH, Raza A, Velez E, Sharma AK, Narayan S. Human-centric modeling in metastatic breast cancer: organoids, organ-on-chip systems, and new approach methodologies in the post-FDA modernization act 2.0 era. Cancers. 2026;18:1166.","journal-title":"Cancers"},{"key":"4201_CR170","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun C-K, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77:1099\u2013109.","journal-title":"JAMA Neurol"},{"key":"4201_CR171","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12951-023-02236-z","volume":"21","author":"J Ren","year":"2023","unstructured":"Ren J, Dewey RB III, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT. Evidence of brain target engagement in Parkinson\u2019s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials. J Nanobiotechnol. 2023;21:478.","journal-title":"J Nanobiotechnol"},{"key":"4201_CR172","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04201-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:23:32Z","timestamp":1790897012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04201-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":172,"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04201-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}